Comparison of 2 Fillers for Lip Injection-A Randomized-Controlled Clinical Trial Assessed by 3D Imaging.

Background: Lip aging is a concern for many, and hyaluronic acid (HA) injections are a popular solution.

Objectives: This study compared 2 different HA gel technologies (OBT and NASHA) for lip augmentation in 20 volunteers.

Methods: Both groups received treatment from the same injector using the same method.

The safety of botulinum neurotoxin type A's intraarticular application in experimental animals.

In vivo studies of botulinum neurotoxin type A (BoNT-A) enabled characterization of its activity in the nociceptive sensory system separate from its preferred action in motor and autonomic nerve terminals. However, in the recent rodent studies of arthritic pain which employed high intra-articular (i.a.

Muscle Function Recovery Following Botulinum Toxin Type A Facial Injections: A Case Managed With Photobiomodulation Therapy.

Aesthetic applications of botulinum toxin type A (BoNT-A) may lead to some complications, including unwanted muscle paralysis. Moreover, BoNT-A effects may last several months, and there is no medical intervention so far to accelerate muscle function recovery. A female patient with a movement disorder of the mimic muscles resulting from BoNT-A injections received daily sessions of photobiomodulation therapy (PBMT).

Myomodulation using hyaluronic acid fillers as an efficient and innovative treatment for gummy smile: A case report.

Myomodulation (MyoMo) using hyaluronic acid (HA) fillers can be considered as a novel aesthetic treatment for gummy smile (GS). However, literature is still lacking information about this procedure. For this reason, the aim of the present case report was to describe a technique for MyoMo with HA as an efficient alternative for the management of GS.

Antinociceptive Actions of Botulinum Toxin A1 on Immunogenic Hypersensitivity in Temporomandibular Joint of Rats.

Botulinum neurotoxin type A1 (BoNT-A) reduces the peripheral peptide and cytokine upregulation in rats with antigen-evoked persistent immunogenic hypersensitivity (PIH) of the temporomandibular joint (TMJ). Herein, we examined the effects of two preparations of BoNT-A, abobotulinumtoxinA (aboBoNT-A; Dysport) and onabotulinumtoxinA (onaBoNT-A; Botox), on spontaneous and evoked nociceptive behaviors, as well as on central neuronal and astroglial activation. The antigen-evoked PIH was induced in rats via repeated systemic and unilateral intra-articular (i.

Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats.

Analgesic mechanism of Botulinum toxin type A (BoNT/A) involves retrograde axonal transport to central nervous system, where it may interact with sensory neurons. Though, some authors suggested that BoNT/A antinociceptive action may also be associated with the inhibition intracellular factors and neuromodulators expressed by immune cells, especially by microglia. Antigen-induced arthritis in the temporomandibular joint (TMJ) of rats is signal by P2X7 receptor/Cathepsin S (CatS)/Fractalkine (FKN) microglia-activated pathway.

Efficacy and Safety of Botulinum Toxin Type A on Persistent Myofascial Pain: A Randomized Clinical Trial.

This study assessed the safety and efficacy of three different doses of BoNT-A for persistent myofascial pain (MFP). One hundred female subjects were randomly assigned into five groups ( = 20): oral appliance (OA), saline solution (SS) and three BoNT-A groups with different doses. Pain intensity and pressure pain threshold were evaluated up to 24 weeks after treatment.

Association between mandibular advancement device therapy and reduction of excessive daytime sleepiness due to obstructive sleep apnoea.

Background: Excessive daytime sleepiness (EDS) is frequently reported as a symptom for obstructive sleep apnoea (OSA), leading to problems with concentration, mood and memory. Mandibular advance device (MAD) is considered as an effective therapy to control OSA, reducing EDS and improving sleep quality.

Objectives: The present study aimed to investigate the effects MAD therapy on EDS of patients diagnosed with OSA.

Association between mandibular advancement device therapy and reduction of Excessive Daytime Sleepiness due to Obstructive Sleep Apnea.

Background: Excessive daytime sleepiness is frequently reported as a symptom for OSA, leading to problems with concentration, mood and memory. MAD are considered as an effective therapy to control OSA, reducing EDS and improving sleep quality.

Objectives: The present study aimed to investigate the effects of mandibular advance device (MAD) therapy on excessive daytime sleepiness (EDS) of patients diagnosed with obstructive sleep apnea (OSA).

Prevalence of psychosocial impairment in temporomandibular disorder patients: A systematic review.

Background: Several studies have described high levels of psychosocial disorders in patients with temporomandibular disorders (TMD), but an estimate of their prevalence in populations of TMD patients has never been assessed systematically.

Objective: To conduct a systematic review of the literature on the prevalence of research diagnostic criteria for TMD (RDC/TMD) Axis II findings in TMD patients.

Methods: Search for articles was carried out by two independent researchers to retrieve papers published after 1992.

Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats.

Objective: This study aimed to investigate the antinociceptive effects of Botulinum toxin type A (BoNT-A) on persistent inflammatory hypernociception induced by arthritis in the temporomandibular joint (TMJ) of rats.

Material And Methods: Wistar rats were induced to persistent inflammatory hypernociception in the left TMJ. Then, animals were treated with intra-TMJ injections of BoNT-A, using doses of 3.

Prevalence of temporomandibular disorders in postmenopausal women and relationship with pain and HRT.

The prevalence of temporomandibular disorders (TMD) is higher in females, reaching their high peak during reproductive years, probably because of the action of some female hormones, which alter pain threshold. This study aimed to investigate the prevalence of TMD in postmenopausal women and its relationship with pain and hormone replacement therapy (HRT). In total, 284 patients were evaluated and classified using the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).